Allogeneic Anti-EGFR Antibody-conjugated Gamma Delta 2 T-cells ACE2016

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** An off-the-shelf preparation of a subset of allogeneic T-lymphocytes, derived from healthy donors, that express only gamma and delta 2 T-cell receptors (TCRs) conjugated, through antibody cell conjugation (ACC), to an antibody targeting the tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR), with potential immunomodulating and antineoplastic activities. The gamma delta 2 T-cells (gd2 T-cells) and the anti-EGFR antibody were covalently conjugated to selected DNA aptamers that enable DNA hybridization to generate EGFR-targeting gd2 T-cells. Upon administration of the allogeneic anti-EGFR antibody-conjugated gd2 T-cells ACE2016, the anti-EGFR antibody targets and binds to EGFR expressed on tumor cells. The gd2 T-cells secrete interferon-gamma (IFN-g) and exert direct killing of the EGFR-expressing tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against EGFR-expressing tumor cells. gd2 T-cells play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. EGFR, a receptor tyrosine kinase overexpressed and/or mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

**Synonyms:** - ACE 2016 - ACE-2016 - ACE2016 - Allogeneic Anti-EGFR Antibody Armed Gamma Delta 2 T-cells ACE2016 - Allogeneic Anti-EGFR Antibody-conjugated gd2 T-cells ACE2016 (SY); Allogeneic gd2 T-cells ACE2016 - Allogeneic Anti-EGFR Conjugated Gamma Delta 2 T Cells ACE2016 - Allogeneic Anti-EGFR T-cells ACE2016 - Allogeneic EGFR-targeting gd2 T-cells ACE2016